If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
2.90    0.05 (1.75%)
Bid:
2.80
Ask:
3.00
Spread: 0.20 (7.143%)
Market Cap: £23.30m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

First Order For Ecovelex

16 Aug 2023 07:00

RNS Number : 4283J
Eden Research plc
16 August 2023
 

16 August 2023

 

 

Eden Research

("Eden" or "the Company")

 

Eden receives its first order for Ecovelex®

 

Eden's new sustainable seed treatment product helps farmers safely repel birds.

 

Eden Research plc (AIM: EDEN; OTCQB: EDNSF), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, today announces that it has received its first commercial order for Ecovelex.

 

Developed by Eden Research over the past three years, Ecovelex represents a new entrant into the seed treatment market and is intended to replace conventional chemicals that are facing significant regulatory pressures in the EU and UK. This new product was developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops.

 

Until full authorisation is received, the use of Ecovelex to treat seeds this year is contingent upon certain countries granting emergency use authorisation. Unless, and until, emergency use approvals are granted, it is difficult to anticipate the full demand in the short term.

 

Following the successful fundraise announced by the Company on 28 July 2023, production of Ecovelex is now underway to fulfil this initial order. It is expected that the order will be shipped towards the end of the year so that, in the event of receipt of relevant regulatory approvals, it will be available in time for the seed treatment window for the 2024 growing season.

 

Sean Smith, Eden CEO, said: "I'm pleased to have received our first commercial order for Ecovelex and am pleased to report that production is underway here in the UK to fulfil the order.

 

At this point in the year, and without visibility on emergency use authorisations, it is not possible to provide guidance on the overall potential financial impact of the Ecovelex sales, however, this order and initial production is clearly a positive step forward for maize growers and the Company."

 

 

 

 

 

 

 

For further information contact:

 

Eden Research plc

Sean SmithAlex Abrey

 

www.edenresearch.com

+44 (0) 1285 359 555

 

 

Cenkos Securities plc (NOMAD and broker to Eden Research plc)

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

+44 (0) 20 7397 8900

Hawthorn Advisors (Financial PR to Eden Research plc)

Simon Woods

Felix Meston

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

About Eden

 

Eden is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information, please visit: www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

 

 

About Ecovelex

 

Ecovelex is new entrant into the seed treatment market developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops and is intended to replace conventional chemicals that are facing significant regulatory pressures in the EU and UK.

 

Ecovelex works by affecting the bird's olfactory system, creating an unpleasant taste or odour that repels the birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry and formulated using the Company's Sustaine® microencapsulation technology, supporting farmers as they strive to meet consumer and regulator demands for more sustainable agriculture.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTNKPBBKBKBKFD
Date   Source Headline
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM
29th May 20207:58 amRNSIssuing of Annual Report & Notice of AGM
27th May 20207:00 amRNSUpdate on Bayer Animal Health Agreement
20th May 20207:00 amRNSNew authorisations for Cedroz and Mevalone
7th May 20207:00 amRNSFinancial Results for Year Ended 31 December 2019
6th May 20205:09 pmRNSNotice of Results
15th Apr 20207:00 amRNSAppointment of Director of Regulatory Affairs
8th Apr 202010:03 amRNSOrganic farming certification in Italy and Spain
24th Mar 20208:20 amRNSHolding(s) in Company
20th Mar 20205:33 pmRNSHolding(s) in Company
20th Mar 20203:37 pmRNSHolding(s) in Company
20th Mar 202010:33 amRNSHolding(s) in Company
18th Mar 202011:18 amRNSResults of General Meeting & Open Offer
5th Mar 20207:00 amRNSDirector/PDMR Shareholding
28th Feb 20201:35 pmRNSPlacing, Subscription & Open Offer
20th Jan 20207:00 amRNSAppointment of Hawthorn Advisors
14th Jan 20207:00 amRNSYear-end trading update
8th Jan 20207:00 amRNSAgreement with Corteva Agriscience
7th Jan 20207:00 amRNSRegulatory Approval- Organic Production Regulation
23rd Dec 20197:00 amRNSAgreement with Sipcam Oxon in Portugal and Benelux
19th Dec 20197:00 amRNSApproval of Cedroz in Mexico
17th Dec 20197:00 amRNSDistribution Agreement with SumiAgro Europe
16th Oct 201912:48 pmRNSDirector/PDMR Shareholding
16th Oct 20197:00 amRNSCedroz Approval
18th Sep 20197:00 amRNSHalf Yearly Report
29th Jul 20197:00 amRNSGrant of 'Emergency use' authorisation
8th Jul 20197:00 amRNSChange of Adviser
28th Jun 20192:42 pmRNSReplacement - Grant of Awards
28th Jun 201911:43 amRNSGrant of Awards under Long-Term Incentive Plan
28th Jun 20197:00 amRNSDirector/PDMR Shareholding
12th Jun 20197:00 amRNSAppointment of Commercial Director
15th May 20198:10 amRNSResult of AGM
14th May 20197:00 amRNSAGM Statement
9th May 20197:00 amRNSSales of Cedroz commence in Italy
26th Apr 20197:00 amRNSItaly grants "emergency use" Cedroz authorisation
16th Apr 201912:43 pmRNSDirector/PDMR Shareholding
16th Apr 20197:00 amRNSIssuing of Annual Report & Notice of AGM
2nd Apr 20197:00 amRNSFinancial Results for Year Ended 31 December 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.